{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000047","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.254940+00:00","generated_at":"2026-06-12T00:44:16.842973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme Q2: revenue $221M, GAAP EPS $0.56, Non-GAAP $0.74; raises FY EPS guidance to $2.65-$2.75","bullets":["Revenue $221.0M, +45% YoY; GAAP diluted EPS $0.56 vs $0.16 YoY; non-GAAP diluted EPS $0.74 vs $0.53.","Royalty revenue record $111.7M (+31% YoY), driven by subcutaneous DARZALEX.","Raised 2023 non-GAAP diluted EPS guidance to $2.65-$2.75 from $2.50-$2.65; revenue guidance $825-$845M.","FDA approval of VYVGART Hytrulo (argenx) for gMG triggered $33M milestones and royalties.","Positive Phase 3 data from Roche's SC ocrelizumab and argenx's CIDP trial support pipeline growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000047","json":"https://secwatch.observer/filing/0001159036-23-000047.json","markdown":"https://secwatch.observer/filing/0001159036-23-000047.md","text":"https://secwatch.observer/filing/0001159036-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000047/0001159036-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000047/halo-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:44:16.842973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}